ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Tuesday, October 28, 2025

10:30AM-12:30PM: Abstract Number: 2432

Duffy Null Genotype and Autoantibodies Synergistically Contribute to Severe Leukopenia in Systemic Lupus Erythematosus

(2377–2436) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2336

Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the “ESPALDA” Multinational Registry

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2324

Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data

(2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2234

Early Sustained Remission Resulted in Superior Long-term Patient-Reported Outcomes in Rheumatoid Arthritis

(2227–2264) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2164

East Meets West: A Novel Tofu-Pasta-Cardstock Phantom Model for Teaching Ultrasound-Guided Procedures

(2159–2194) Professional Education Poster

10:30AM-12:30PM: Abstract Number: 1929

Economic Burden of Macrophage Activation Syndrome (MAS) in Patients with Still’s Disease (Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s Disease (AOSD)): Analysis of a US National Administrative Claims Database

(1914–1935) Health Services Research Poster III

10:30AM-12:30PM: Abstract Number: 2179

Educational online webinars of European Reference Network (ERN) on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ReCONNET) for patients, caregivers and healthcare professionals: six years’ experience

(2159–2194) Professional Education Poster

10:30AM-10:45AM: Abstract Number: 1748

Effect of Air Pollution on Disease Activity in Patients with Rheumatoid Arthritis

Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes I: Breathe (ILD/Pulmonary) (1746–1751)

10:30AM-12:30PM: Abstract Number: 2498

Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease

(2470–2503) Systemic Sclerosis & Related Disorders – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2440

Effect of Cenerimod on Four Main Clinical Items of SLEDAI-2K Score in SLE Patients in a Phase 2b Study

(2437–2469) Systemic Lupus Erythematosus – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2282

Effect of Online Continuing Education on Advancing Care for Rheumatoid Arthritis: A Real-World Outcome Analysis

(2265–2289) Rheumatoid Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2110

Effect of Proton-Pump-Inhibitors on Bone Mineral Density and Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases

(2106–2123) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 2373

Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study

(2338–2376) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III

10:30AM-12:30PM: Abstract Number: 2016

Effectiveness of Nintedanib combined with different DMARDs in joint and pulmonary domains of Rheumatoid Arthritis – Interstitial Lung Disease. National multicenter study of 74 patients

(2015–2051) Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2205

Effectiveness of Reproductive Health Counseling for Rheumatology Patients

(2195–2226) Reproductive Issues in Rheumatic Disorders Posters

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].